{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:05:49Z","timestamp":1790175949940,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15654-7","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T23:56:06Z","timestamp":1769817366000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["P300 enhances glycolysis and dox resistance in DLBCL by upregulating HK2 expression through histone lactylation"],"prefix":"10.1186","volume":"26","author":[{"given":"Xiangxiang","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huazhen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasha","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"issue":"2","key":"15654_CR1","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.critrevonc.2012.12.009","volume":"87","author":"M Martelli","year":"2013","unstructured":"Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol\/Hematol. 2013;87(2):146\u201371.","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"15654_CR2","doi-asserted-by":"crossref","unstructured":"Stegemann M, Denker S, Schmitt CA. DLBCL 1L-What to expect beyond R-CHOP? Cancers (Basel). 2022;14(6):1453.","DOI":"10.3390\/cancers14061453"},{"issue":"3","key":"15654_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/CM9.0000000000001294","volume":"134","author":"L Wang","year":"2020","unstructured":"Wang L, Li LR. R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms. Chin Med J (Engl). 2020;134(3):253\u201360.","journal-title":"Chin Med J (Engl)"},{"issue":"12","key":"15654_CR4","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.7150\/jca.85906","volume":"14","author":"Z Chen","year":"2023","unstructured":"Chen Z, Wang T, Li C, Zhang W, Huang W, Xue J, Wang J, Li S. FOXP1-GINS1 axis promotes DLBCL proliferation and directs doxorubicin resistance. J Cancer. 2023;14(12):2289\u2013300.","journal-title":"J Cancer"},{"key":"15654_CR5","doi-asserted-by":"publisher","first-page":"110831","DOI":"10.1016\/j.cellsig.2023.110831","volume":"110","author":"X Lu","year":"2023","unstructured":"Lu X, Zhang Q, Xie Y. TCFL5 knockdown sensitizes DLBCL to doxorubicin treatment via regulation of GPX4. Cell Signal. 2023;110:110831.","journal-title":"Cell Signal"},{"issue":"11","key":"15654_CR6","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nrm3890","volume":"15","author":"P Tessarz","year":"2014","unstructured":"Tessarz P, Kouzarides T. Histone core modifications regulating nucleosome structure and dynamics. Nat Rev Mol Cell Biol. 2014;15(11):703\u20138.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7674","key":"15654_CR7","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nature24028","volume":"550","author":"LM Lasko","year":"2017","unstructured":"Lasko LM, Jakob CG, Edalji RP, Qiu W, Montgomery D, Digiammarino EL, Hansen TM, Risi RM, Frey R, Manaves V, et al. Discovery of a selective catalytic p300\/CBP inhibitor that targets lineage-specific tumours. Nature. 2017;550(7674):128\u201332.","journal-title":"Nature"},{"key":"15654_CR8","doi-asserted-by":"crossref","unstructured":"Zeng Q, Wang K, Zhao Y, Ma Q, Chen Z, Huang W. Effects of the acetyltransferase p300 on tumour regulation from the novel perspective of posttranslational protein modification. Biomolecules. 2023;13(3):417.","DOI":"10.3390\/biom13030417"},{"issue":"11","key":"15654_CR9","doi-asserted-by":"publisher","first-page":"4935","DOI":"10.7150\/thno.73223","volume":"12","author":"Q Chen","year":"2022","unstructured":"Chen Q, Yang B, Liu X, Zhang XD, Zhang L, Liu T. Histone acetyltransferases CBP\/p300 in tumorigenesis and CBP\/p300 inhibitors as promising novel anticancer agents. Theranostics. 2022;12(11):4935\u201348.","journal-title":"Theranostics"},{"issue":"1","key":"15654_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s13046-023-02777-z","volume":"42","author":"M Zhang","year":"2023","unstructured":"Zhang M, Kan D, Zhang B, Chen X, Wang C, Chen S, Gao W, Yang Z, Li Y, Chen Y, et al. P300\/SP1 complex mediating elevated METTL1 regulates CDK14 mRNA stability via internal m7G modification in CRPC. J Exp Clin Cancer Res. 2023;42(1):215.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"15654_CR11","doi-asserted-by":"publisher","first-page":"7253","DOI":"10.18632\/oncotarget.6635","volume":"7","author":"D Paladino","year":"2016","unstructured":"Paladino D, Yue P, Furuya H, Acoba J, Rosser CJ, Turkson J. A novel nuclear Src and p300 signaling axis controls migratory and invasive behavior in pancreatic cancer. Oncotarget. 2016;7(6):7253\u201367.","journal-title":"Oncotarget"},{"issue":"19","key":"15654_CR12","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1038\/s41388-020-1270-z","volume":"39","author":"J Liu","year":"2020","unstructured":"Liu J, He D, Cheng L, Huang C, Zhang Y, Rao X, Kong Y, Li C, Zhang Z, Liu J, et al. p300\/CBP Inhibition enhances the efficacy of programmed death-ligand 1 Blockade treatment in prostate cancer. Oncogene. 2020;39(19):3939\u201351.","journal-title":"Oncogene"},{"issue":"5","key":"15654_CR13","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.molcel.2018.05.035","volume":"70","author":"H Huang","year":"2018","unstructured":"Huang H, Tang S, Ji M, Tang Z, Shimada M, Liu X, Qi S, Locasale JW, Roeder RG, Zhao Y, et al. : p300-Mediated lysine 2-Hydroxyisobutyrylation regulates Glycolysis. Mol Cell. 2018;70(5):984.","journal-title":"Mol Cell"},{"issue":"34","key":"15654_CR14","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1038\/sj.onc.1209597","volume":"25","author":"H Pelicano","year":"2006","unstructured":"Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis Inhibition for anticancer treatment. Oncogene. 2006;25(34):4633\u201346.","journal-title":"Oncogene"},{"issue":"2","key":"15654_CR15","first-page":"219","volume":"48","author":"L Xu","year":"2019","unstructured":"Xu L, Xu M, Tong X. [Effects of aerobic Glycolysis on pathogenesis and drug resistance of non-Hodgkin lymphoma]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2019;48(2):219\u201323.","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"15654_CR16","doi-asserted-by":"publisher","first-page":"101758","DOI":"10.1016\/j.tranon.2023.101758","volume":"37","author":"MR Pandkar","year":"2023","unstructured":"Pandkar MR, Sinha S, Samaiya A, Shukla S. Oncometabolite lactate enhances breast cancer progression by orchestrating histone lactylation-dependent c-Myc expression. Transl Oncol. 2023;37:101758.","journal-title":"Transl Oncol"},{"key":"15654_CR17","doi-asserted-by":"publisher","first-page":"949252","DOI":"10.3389\/fgene.2022.949252","volume":"13","author":"Y Xie","year":"2022","unstructured":"Xie Y, Hu H, Liu M, Zhou T, Cheng X, Huang W, Cao L. The role and mechanism of histone lactylation in health and diseases. Front Genet. 2022;13:949252.","journal-title":"Front Genet"},{"issue":"4","key":"15654_CR18","doi-asserted-by":"publisher","first-page":"296","DOI":"10.2174\/1389557516666160630124938","volume":"18","author":"J Wei","year":"2018","unstructured":"Wei J, Yang Y, Lu M, Lei Y, Xu L, Jiang Z, Xu X, Guo X, Zhang X, Sun H, et al. Recent advances in the discovery of HIF-1\u03b1-p300\/CBP inhibitors as Anti-Cancer agents. Mini Rev Med Chem. 2018;18(4):296\u2013309.","journal-title":"Mini Rev Med Chem"},{"issue":"6","key":"15654_CR19","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.3892\/ijo.2013.1907","volume":"42","author":"R Rajendran","year":"2013","unstructured":"Rajendran R, Garva R, Ashour H, Leung T, Stratford I, Krstic-Demonacos M, Demonacos C. Acetylation mediated by the p300\/CBP-associated factor determines cellular energy metabolic pathways in cancer. Int J Oncol. 2013;42(6):1961\u201372.","journal-title":"Int J Oncol"},{"issue":"3","key":"15654_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.tibs.2019.12.004","volume":"45","author":"MV Liberti","year":"2020","unstructured":"Liberti MV, Locasale JW. Histone lactylation: A new role for glucose metabolism. Trends Biochem Sci. 2020;45(3):179\u201382.","journal-title":"Trends Biochem Sci"},{"issue":"10","key":"15654_CR21","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1038\/leu.2017.45","volume":"31","author":"HQ Ju","year":"2017","unstructured":"Ju HQ, Zhan G, Huang A, Sun Y, Wen S, Yang J, Lu WH, Xu RH, Li J, Li Y, et al. ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic Inhibition. Leukemia. 2017;31(10):2143\u201350.","journal-title":"Leukemia"},{"issue":"9","key":"15654_CR22","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1158\/1541-7786.MCR-09-0234","volume":"7","author":"D Palmieri","year":"2009","unstructured":"Palmieri D, Fitzgerald D, Shreeve SM, Hua E, Bronder JL, Weil RJ, Davis S, Stark AM, Merino MJ, Kurek R, et al. Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol Cancer Res. 2009;7(9):1438\u201345.","journal-title":"Mol Cancer Res"},{"issue":"1a","key":"15654_CR23","first-page":"251","volume":"27","author":"M Rho","year":"2007","unstructured":"Rho M, Kim J, Jee CD, Lee YM, Lee HE, Kim MA, Lee HS, Kim WH. Expression of type 2 hexokinase and mitochondria-related genes in gastric carcinoma tissues and cell lines. Anticancer Res. 2007;27(1a):251\u20138.","journal-title":"Anticancer Res"},{"issue":"8","key":"15654_CR24","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.cmet.2023.06.013","volume":"35","author":"H Rho","year":"2023","unstructured":"Rho H, Terry AR, Chronis C, Hay N. Hexokinase 2-mediated gene expression via histone lactylation is required for hepatic stellate cell activation and liver fibrosis. Cell Metab. 2023;35(8):1406\u2013e14231408.","journal-title":"Cell Metab"},{"key":"15654_CR25","doi-asserted-by":"publisher","first-page":"833694","DOI":"10.3389\/fgene.2022.833694","volume":"13","author":"S Fang","year":"2022","unstructured":"Fang S, Peng B, Wen Y, Yang J, Wang H, Wang Z, Qian K, Wei Y, Jiao Y, Gao C, et al. Transcriptome-Wide analysis of RNA N(6)-Methyladenosine modification in Adriamycin-Resistant acute myeloid leukemia cells. Front Genet. 2022;13:833694.","journal-title":"Front Genet"},{"issue":"3","key":"15654_CR26","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12033-013-9672-6","volume":"55","author":"SC Taylor","year":"2013","unstructured":"Taylor SC, Berkelman T, Yadav G, Hammond M. A defined methodology for reliable quantification of Western blot data. Mol Biotechnol. 2013;55(3):217\u201326.","journal-title":"Mol Biotechnol"},{"issue":"1","key":"15654_CR27","first-page":"173","volume":"5","author":"A Takeuchi","year":"2012","unstructured":"Takeuchi A, Shiota M, Tatsugami K, Yokomizo A, Tanaka S, Kuroiwa K, Eto M, Naito S. p300 mediates cellular resistance to doxorubicin in bladder cancer. Mol Med Rep. 2012;5(1):173\u20136.","journal-title":"Mol Med Rep"},{"issue":"4","key":"15654_CR28","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.molcel.2018.04.011","volume":"70","author":"H Huang","year":"2018","unstructured":"Huang H, Tang S, Ji M, Tang Z, Shimada M, Liu X, Qi S, Locasale JW, Roeder RG, Zhao Y, et al. : p300-Mediated lysine 2-Hydroxyisobutyrylation regulates Glycolysis. Mol Cell. 2018;70(4):663\u2013e678666.","journal-title":"Mol Cell"},{"issue":"1","key":"15654_CR29","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41392-022-01151-3","volume":"7","author":"X Li","year":"2022","unstructured":"Li X, Yang Y, Zhang B, Lin X, Fu X, An Y, Zou Y, Wang JX, Wang Z, Yu T. Lactate metabolism in human health and disease. Signal Transduct Target Ther. 2022;7(1):305.","journal-title":"Signal Transduct Target Ther"},{"key":"15654_CR30","doi-asserted-by":"crossref","unstructured":"Klener P, Klanova M. Drug resistance in Non-Hodgkin lymphomas. Int J Mol Sci. 2020;21(6):2081.","DOI":"10.3390\/ijms21062081"},{"key":"15654_CR31","doi-asserted-by":"publisher","first-page":"100822","DOI":"10.1016\/j.drup.2022.100822","volume":"61","author":"M Pi","year":"2022","unstructured":"Pi M, Kuang H, Yue C, Yang Q, Wu A, Li Y, Assaraf YG, Yang DH, Wu S. Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma. Drug Resist Updat. 2022;61:100822.","journal-title":"Drug Resist Updat"},{"issue":"6","key":"15654_CR32","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/bph.13422","volume":"173","author":"B Bhattacharya","year":"2016","unstructured":"Bhattacharya B, Mohd Omar MF, Soong R. The Warburg effect and drug resistance. Br J Pharmacol. 2016;173(6):970\u20139.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"15654_CR33","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1586\/14737140.4.3.449","volume":"4","author":"JF Geschwind","year":"2004","unstructured":"Geschwind JF, Georgiades CS, Ko YH, Pedersen PL. Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma. Expert Rev Anticancer Ther. 2004;4(3):449\u201357.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"22","key":"15654_CR34","doi-asserted-by":"publisher","first-page":"6921","DOI":"10.1158\/0008-5472.CAN-11-1457","volume":"71","author":"F Hirschhaeuser","year":"2011","unstructured":"Hirschhaeuser F, Sattler UG, Mueller-Klieser W. Lactate: a metabolic key player in cancer. Cancer Res. 2011;71(22):6921\u20135.","journal-title":"Cancer Res"},{"issue":"1","key":"15654_CR35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13046-020-1528-x","volume":"39","author":"J Feng","year":"2020","unstructured":"Feng J, Dai W, Mao Y, Wu L, Li J, Chen K, Yu Q, Kong R, Li S, Zhang J, et al. Simvastatin re-sensitizes hepatocellular carcinoma cells to Sorafenib by inhibiting HIF-1alpha\/PPAR-gamma\/PKM2-mediated Glycolysis. J Exp Clin Cancer Res. 2020;39(1):24.","journal-title":"J Exp Clin Cancer Res"},{"key":"15654_CR36","doi-asserted-by":"crossref","unstructured":"Wu H, Du J, Li C, Li H, Guo H, Li Z. Kaempferol can reverse the 5-Fu resistance of colorectal cancer cells by inhibiting PKM2-Mediated Glycolysis. Int J Mol Sci. 2022;23(7):3544.","DOI":"10.3390\/ijms23073544"},{"issue":"2","key":"15654_CR37","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41375-022-01769-w","volume":"37","author":"SK Lim","year":"2023","unstructured":"Lim SK, Peng CC, Low S, Vijay V, Budiman A, Phang BH, Lim JQ, Jeyasekharan AD, Lim ST, Ong CK, et al. Sustained activation of non-canonical NF-kappaB signalling drives glycolytic reprogramming in doxorubicin-resistant DLBCL. Leukemia. 2023;37(2):441\u201352.","journal-title":"Leukemia"},{"issue":"9","key":"15654_CR38","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1111\/cas.15055","volume":"112","author":"D Jiang","year":"2021","unstructured":"Jiang D, Mo Q, Sun X, Wang X, Dong M, Zhang G, Chen F, Zhao Q. Pyruvate dehydrogenase kinase 4-mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B-cell lymphoma by affecting the expression of MS4A1\/CD20. Cancer Sci. 2021;112(9):3585\u201397.","journal-title":"Cancer Sci"},{"issue":"2","key":"15654_CR39","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3892\/ijo.2015.3288","volume":"48","author":"Y Inagaki","year":"2016","unstructured":"Inagaki Y, Shiraki K, Sugimoto K, Yada T, Tameda M, Ogura S, Yamamoto N, Takei Y, Ito M. Epigenetic regulation of proliferation and invasion in hepatocellular carcinoma cells by CBP\/p300 histone acetyltransferase activity. Int J Oncol. 2016;48(2):533\u201340.","journal-title":"Int J Oncol"},{"issue":"4","key":"15654_CR40","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1158\/0008-5472.CAN-20-1323","volume":"81","author":"LY Cai","year":"2021","unstructured":"Cai LY, Chen SJ, Xiao SH, Sun QJ, Ding CH, Zheng BN, Zhu XY, Liu SQ, Yang F, Yang YX, et al. Targeting p300\/CBP attenuates hepatocellular carcinoma progression through epigenetic regulation of metabolism. Cancer Res. 2021;81(4):860\u201372.","journal-title":"Cancer Res"},{"issue":"5","key":"15654_CR41","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.14336\/AD.2022.0218","volume":"13","author":"X Wang","year":"2022","unstructured":"Wang X, Wang Z, Huang R, Lu Z, Chen X, Huang D. UPP1 promotes lung adenocarcinoma progression through epigenetic regulation of Glycolysis. Aging Dis. 2022;13(5):1488\u2013503.","journal-title":"Aging Dis"},{"issue":"1","key":"15654_CR42","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/bjd.13226","volume":"172","author":"MK Chen","year":"2015","unstructured":"Chen MK, Cai MY, Luo RZ, Tian X, Liao QM, Zhang XY, Han JD. Overexpression of p300 correlates with poor prognosis in patients with cutaneous squamous cell carcinoma. Br J Dermatol. 2015;172(1):111\u20139.","journal-title":"Br J Dermatol"},{"key":"15654_CR43","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1479-5876-9-5","volume":"9","author":"M Li","year":"2011","unstructured":"Li M, Luo RZ, Chen JW, Cao Y, Lu JB, He JH, Wu QL, Cai MY. High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinoma. J Transl Med. 2011;9:5.","journal-title":"J Transl Med"},{"issue":"5","key":"15654_CR44","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.athoracsur.2010.12.012","volume":"91","author":"Y Li","year":"2011","unstructured":"Li Y, Yang HX, Luo RZ, Zhang Y, Li M, Wang X, Jia WH. High expression of p300 has an unfavorable impact on survival in resectable esophageal squamous cell carcinoma. Ann Thorac Surg. 2011;91(5):1531\u20138.","journal-title":"Ann Thorac Surg"},{"key":"15654_CR45","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/1479-5876-10-110","volume":"10","author":"ZW Liao","year":"2012","unstructured":"Liao ZW, Zhou TC, Tan XJ, Song XL, Liu Y, Shi XY, Huang WJ, Du LL, Tu BJ, Lin XD. High expression of p300 is linked to aggressive features and poor prognosis of nasopharyngeal carcinoma. J Transl Med. 2012;10:110.","journal-title":"J Transl Med"},{"issue":"4","key":"15654_CR46","doi-asserted-by":"publisher","first-page":"a019521","DOI":"10.1101\/cshperspect.a019521","volume":"8","author":"JE Audia","year":"2016","unstructured":"Audia JE, Campbell RM. Histone modifications and cancer. Cold Spring Harb Perspect Biol. 2016;8(4):a019521.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"15654_CR47","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13059-021-02308-z","volume":"22","author":"J Yu","year":"2021","unstructured":"Yu J, Chai P, Xie M, Ge S, Ruan J, Fan X, Jia R. Histone lactylation drives oncogenesis by facilitating m(6)A reader protein YTHDF2 expression in ocular melanoma. Genome Biol. 2021;22(1):85.","journal-title":"Genome Biol"},{"issue":"9","key":"15654_CR48","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.molcel.2022.02.033","volume":"82","author":"J Xiong","year":"2022","unstructured":"Xiong J, He J, Zhu J, Pan J, Liao W, Ye H, Wang H, Song Y, Du Y, Cui B, et al. Lactylation-driven METTL3-mediated RNA m(6)A modification promotes immunosuppression of tumor-infiltrating myeloid cells. Mol Cell. 2022;82(9):1660\u201377. e1610.","journal-title":"Mol Cell"},{"issue":"8","key":"15654_CR49","first-page":"684","volume":"45","author":"QY Sun","year":"2023","unstructured":"Sun QY, Zhou Y, Du LJ, Zhang MK, Wang JL, Ren YY, Liu F. Analysis between macrophage-related genes with prognosis and tumor microenvironment in non-small cell lung cancer. Yi Chuan. 2023;45(8):684\u201399.","journal-title":"Yi Chuan"},{"issue":"4","key":"15654_CR50","doi-asserted-by":"publisher","first-page":"296","DOI":"10.2174\/1389557516666160630124938","volume":"18","author":"J Wei","year":"2018","unstructured":"Wei J, Yang Y, Lu M, Lei Y, Xu L, Jiang Z, Xu X, Guo X, Zhang X, Sun H, et al. Recent advances in the discovery of HIF-1alpha-p300\/CBP inhibitors as Anti-Cancer agents. Mini Rev Med Chem. 2018;18(4):296\u2013309.","journal-title":"Mini Rev Med Chem"},{"issue":"1","key":"15654_CR51","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrc706","volume":"2","author":"MM Gottesman","year":"2002","unstructured":"Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2(1):48\u201358.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"15654_CR52","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/S0891-5849(01)00480-4","volume":"30","author":"FQ Schafer","year":"2001","unstructured":"Schafer FQ, Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide\/glutathione couple. Free Radic Biol Med. 2001;30(11):1191\u2013212.","journal-title":"Free Radic Biol Med"},{"issue":"1\u20132","key":"15654_CR53","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0005-2728(98)00119-4","volume":"1366","author":"F Ichas","year":"1998","unstructured":"Ichas F, Mazat JP. From calcium signaling to cell death: two conformations for the mitochondrial permeability transition pore. Switching from low- to high-conductance state. Biochim Biophys Acta. 1998;1366(1\u20132):33\u201350.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"15654_CR54","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s42255-022-00710-w","volume":"5","author":"Z Yang","year":"2023","unstructured":"Yang Z, Yan C, Ma J, Peng P, Ren X, Cai S, Shen X, Wu Y, Zhang S, Wang X, et al. Lactylome analysis suggests lactylation-dependent mechanisms of metabolic adaptation in hepatocellular carcinoma. Nat Metab. 2023;5(1):61\u201379.","journal-title":"Nat Metab"},{"issue":"11","key":"15654_CR55","doi-asserted-by":"publisher","first-page":"9194","DOI":"10.1021\/acs.jmedchem.4c00335","volume":"67","author":"T Wu","year":"2024","unstructured":"Wu T, Hu J, Zhao X, Zhang C, Dong R, Hu Q, Xu H, Shen H, Zhang X, Zhang Y, et al. Discovery of a promising CBP\/p300 degrader XYD129 for the treatment of acute myeloid leukemia. J Med Chem. 2024;67(11):9194\u2013213.","journal-title":"J Med Chem"},{"issue":"1","key":"15654_CR56","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41392-024-01859-4","volume":"9","author":"Y Yang","year":"2024","unstructured":"Yang Y, Liu Q, Wang M, Li L, Yu Y, Pan M, Hu D, Chu B, Qu Y, Qian Z. Genetically programmable cell membrane-camouflaged nanoparticles for targeted combination therapy of colorectal cancer. Signal Transduct Target Ther. 2024;9(1):158.","journal-title":"Signal Transduct Target Ther"},{"issue":"16","key":"15654_CR57","doi-asserted-by":"publisher","first-page":"e2423677122","DOI":"10.1073\/pnas.2423677122","volume":"122","author":"Y Ma","year":"2025","unstructured":"Ma Y, Zhang Z, Cao X, Guo D, Huang S, Xie L, Wu M, Li J, Li C, Chu Y, et al. Semaphorin 6A phase separation sustains a histone lactylation-dependent lactate buildup in pathological angiogenesis. Proc Natl Acad Sci U S A. 2025;122(16):e2423677122.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"15654_CR58","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.cmet.2023.10.002","volume":"35","author":"J Li","year":"2023","unstructured":"Li J, Zheng C, Mai Q, Huang X, Pan W, Lu J, Chen Z, Zhang S, Zhang C, Huang H, et al. Tyrosine catabolism enhances genotoxic chemotherapy by suppressing translesion DNA synthesis in epithelial ovarian cancer. Cell Metab. 2023;35(11):2044\u201359. e2048.","journal-title":"Cell Metab"},{"issue":"10","key":"15654_CR59","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/0008-5472.CAN-18-2799","volume":"79","author":"S Xu","year":"2019","unstructured":"Xu S, Zhou T, Doh HM, Trinh KR, Catapang A, Lee JT, Braas D, Bayley NA, Yamada RE, Vasuthasawat A, et al. An HK2 antisense oligonucleotide induces synthetic lethality in HK1(-)HK2(+) multiple myeloma. Cancer Res. 2019;79(10):2748\u201360.","journal-title":"Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15654-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15654-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15654-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T11:02:39Z","timestamp":1772190159000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15654-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15654"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15654-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal experiments were conducted following the \u201cGuiding Principles in the Care and Use of Animals\u201d (China) and approved by the Laboratory Animal Ethics Committee of Zhejiang Cancer Hospital (NO. 2024ky218).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"308"}}